Pharmacokinetics, bioavailability, & bioequivalence Original research| Volume 33, ISSUE 6, P766-775, June 2011

Single-Dose Bioequivalence of 105-mg Fenofibric Acid Tablets Versus 145-mg Fenofibrate Tablets Under Fasting and Fed Conditions: A Report of Two Phase I, Open-Label, Single-Dose, Randomized, Crossover Clinical Trials



      Fenofibrate is used to treat primary hypercholesterolemia, mixed lipidemia, and hypertriglyceridemia in adults who do not respond to nonpharmacologic measures. Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety. A new orally administered agent, fenofibric acid, was developed as an alternative to fenofibrate.


      Two separate studies were conducted to evaluate the bioequivalence of fenofibric acid relative to fenofibrate under fasted and fed (standard breakfast) conditions, characterize the pharmacokinetic profile, and assess the safety and tolerability of fenofibric acid.


      In study 1 (fasted), during each study period, volunteers received a single 105-mg dose of fenofibric acid or single 145-mg dose of fenofibrate (depending on their randomization scheme) after an overnight fast (a minimum fast of 10 hours). A 7-day washout period followed the first treatment period, after which the volunteers received the alternate treatment. Study 2 followed a similar dosing scheme and differed only in that volunteers received their single dose after being fed a standard meal (575 calories, of which 36% were contributed by fat). Serial blood samples in both studies were collected up to 72 hours after drug administration. The pharmacokinetic parameters of interest for assessing bioequivalence were AUC0–t, AUC0–∞, Cmax, and Tmax. The criterion for a lack of difference between products was a 90% CI between 0.80 and 1.25 for the fenofibric acid:fenofibrate ratios for AUC0–t, AUC0–∞, and Cmax. Tolerability was assessed by adverse events (AEs), laboratory parameters, vital signs, and physical examinations.


      Volunteers in study 1 (fasted; n = 54) were aged 18 to 43 years; 19 (35%) were men and 35 (65%) were women; mean weight was 155.2 pounds (range, 103.0–267.0 pounds); and 48 (89%) were white, 1 (2%) was black, and 5 (9%) were white/American Indian/Alaskan native/Asian. Volunteers in study 2 (fed; n = 54) were aged 18 to 43 years; 27 (50%) were men and 27 (50%) were women; mean weight was 161.9 pounds (range, 112.0–225.0 pounds); and 51 (94%) were white (including 2 Hispanic) and 3 (6%) were black. The 90% CIs about the ratio of the fenofibric acid geometric mean to the fenofibrate geometric mean were within the 80% and 125% limits for the pharmacokinetic parameters Cmax, AUC0–t, and AUC0–∞ of the ln-transformed data in both study 1 (fasted) and study 2. In study 1 (fasted), 14 volunteers (26%) experienced a total of 29 AEs; the most common nonlaboratory AEs were dizziness (6%) and headache (4%). In study 2, 12 volunteers (22%) experienced a total of 19 AEs; the most common nonlaboratory AEs were headache (17%) and dry throat (4%). AEs were generally mild or moderate in intensity.


      In these 2 single-dose studies, these healthy volunteers administered a single oral dose of 105-mg fenofibric acid met the US Food and Drug Administration regulatory criteria for assuming bioequivalence to a single oral dose of 145-mg fenofibrate tablets with respect to the rate and extent of fenofibric acid absorption in both fed and fasted states. Fenofibric acid at the dose studied was well tolerated in this population. identifiers: NCT00961116 and NCT00960687.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Keating G.M.
        • Croom K.F.
        Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
        Drugs. 2007; 67: 121-153
        • Sharpe M.
        • Ormrod D.
        • Jarvis B.
        Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
        Am J Cardiovasc Drugs. 2002; 2: 125-132
        • Keating G.M.
        • Ormrod D.
        Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
        Drugs. 2002; 62: 1909-1944
        • Guivarc'h P.H.
        • Vachon M.G.
        • Fordyce D.
        A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.
        Clin Ther. 2004; 26: 1456-1469
        • Najib J.
        Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
        Clin Ther. 2002; 24: 2022-2050
        • Tziomalos K.
        • Athyros V.G.
        Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.
        Int J Nanomedicine. 2006; 1: 129-147
        • Sauron R.
        • Wilkins M.
        • Jessent V.
        • et al.
        Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.
        Int J Clin Pharmacol Ther. 2006; 44: 64-70
        • US Department of Health and Human Services
        FDA approval letter for Tricor.
        (Accessed September 1, 2010)
      1. Declaration of Helsinki; adopted by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000.
        (Accessed May 19, 2011)
        • US Department of Health and Human Services
        Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations.
        (Published March 2003. Accessed June 1, 2010)
        • LaPorta M.A.
        • Linde H.W.
        • Bruce D.L.
        • Fitzsimons E.J.
        Elevation of creatine phosphokinase in young men after recreational exercise.
        JAMA. 1978; 239: 2685-2686